) boasts of an interesting and diversified pipeline. Multiple
pipeline-related news are expected in the coming quarters.
Celgene is highly optimistic on the potential of apremilast,
which is being developed for multiple indications such as
moderate-to-severe psoriasis and psoriatic arthritis among
ACTELION LTD (ALIOF): Get Free Report
ALEXION PHARMA (ALXN): Free Stock Analysis
ATHERSYS INC (ATHX): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis
To read this article on Zacks.com click here.
Celgene is seeking U.S. approval for apremilast in the psoriatic
arthritis indication. Approval has also been sought for the same
indication in Canada. Celgene is also evaluating apremilast in
patients suffering from moderate-to-severe psoriasis. U.S.
approval for the moderate-to-severe psoriasis indication is
expected to be sought by Dec 31, 2013. Moreover, Celgene intends
to seek EU approval for apremilast in the psoriasis and psoriatic
arthritis indications by year end.
Results of pre-specified sub-analyses from the phase III (ESTEEM
1) study revealed significant improvement in apremilast treated
patients suffering from nail and scalp psoriasis at 16 weeks.
Results further revealed that the patients continued to show
improvements through 32 weeks. Moreover, apremilast treatment
caused significant improvements in health-related quality-of-life
parameters in plaque psoriasis patients. The improvements
witnessed at week 16 were maintained through week 32.
Apremilast is also undergoing phase III studies in the ankylosing
spondylitis indication. The candidate is also being evaluated for
treating patients suffering from Behçet's disease (encouraging
results from a phase II study were presented in Jun 2013).
Celgene is also advancing the development of the early-stage
candidates in its pipeline. We believe that the successful
development and commercialization of the pipeline would boost
Celgene's top line further.
Celgene, a biopharmaceutical company, currently carries a Zacks
Rank #3 (Hold).
Alexion Pharmaceuticals, Inc.
) appear to be well placed in the biopharma space. Actelion
carries a Zacks Rank #1 (Strong Buy) while Alexion and Athersys
are Zacks #2 Ranked (Buy) stocks.